Drugs / TALMAPIMOD
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00508768 | ? → Dec 2002 | rheumatoid arthritis | Scios, Inc. | Completed | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT00113893 | May 2005 → Dec 2007 | bone marrow neoplasm, myelodysplastic syndrome | Scios, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00095680 | Nov 2004 → Feb 2006 | plasma cell myeloma | Scios, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00089921 | Jul 2004 → Oct 2005 | rheumatoid arthritis | Scios, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00087867 | Jun 2004 → Sep 2005 | plasma cell myeloma | Scios, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00043732 | ? → Sep 2003 | rheumatoid arthritis | Scios, Inc. | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TALMAPIMOD | ChEMBL registry synonym — accepted as the source's own label CHEMBL514201 ↗ |
| Known as | SCIO-469 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00113893 ↗ |
| Action | Inhibit | “MAP kinase p38 alpha inhibitor” CHEMBL514201 ↗1“inhibit p38 kinase” NCT00043732 ↗ |
| Modality | Small molecule | — CHEMBL514201 ↗ |
| Route | Oral | “Patients took SCIO-469 two capsules (60 mg) by mouth three times a day” NCT00087867 ↗ |
| Target | MAPK14 | “MAP kinase p38 alpha inhibitor” CHEMBL514201 ↗ |